Drug Res (Stuttg) 2021; 71(02): 94-103
DOI: 10.1055/a-1290-0119
Original Article

Design, Synthesis and Enhanced BBB Penetration Studies of L-serine-Tethered Nipecotic Acid-Prodrug

1   MM College of Pharmacy, MM (Deemed to be University), Mullana, Ambala, Haryana
,
1   MM College of Pharmacy, MM (Deemed to be University), Mullana, Ambala, Haryana
,
Dinesh Kumar Mehta
1   MM College of Pharmacy, MM (Deemed to be University), Mullana, Ambala, Haryana
,
Rina Das
1   MM College of Pharmacy, MM (Deemed to be University), Mullana, Ambala, Haryana
› Institutsangaben
Funding The authors want to thank to MM College of Pharmacy, MM (Deemed to be University), for all the financial supports for the work.

Abstract

Nipecotic acid is considered to be one of the most potent inhibitors of neuronal and glial-aminobutyric acid (GABA) uptake in vitro. Due to its hydrophilic nature, nipecotic acid does not readily cross the blood-brain barrier (BBB). Large neutral amino acids (LAT1)-knotted nipecotic acid prodrug was designed and synthesized with the aim to enhance the BBB permeation by the use of carrier-mediated transport. The synthesized prodrug was tested in animal models of Pentylenetetrazole (PTZ)-induced convulsions in mice. Further pain studies were carried out followed by neurotoxicity estimation by writhing and rota-rod test respectively. HPLC data suggests that the synthesized prodrug has improved penetration through BBB. Nipecotic acid-L-serine ester prodrug with considerable anti-epileptic activity, and the ability to permeate the BBB has been successfully synthesized. [Graphical Abstract].

Zoom Image
Graphical Abstract



Publikationsverlauf

Eingereicht: 14. August 2020

Angenommen: 12. Oktober 2020

Artikel online veröffentlicht:
25. November 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 Davies JA. Mechanisms of action of antiepileptic drugs. Seizure Eur. J Epilepsy 1995; 4: 267-271
  • 2 Löscher W, Schmidt D. New horizons in the development of antiepileptic drugs: Innovative strategies. In: Epilepsy Research 2006; 69: 183-272
  • 3 Abou-Khalil BW. Update on Antiepileptic Drugs 2019. Contin Lifelong Learn Neurol 2019; 25: 508-536
  • 4 Eulenburg V, Gomeza J. Neurotransmitter transporters expressed in glial cells as regulators of synapse function. Brain Res Rev 2010; 63: 103-112
  • 5 Oakley JC, Cho AR, Cheah CS. et al. Synergistic GABA-enhancing therapy against seizures in a mouse model of dravet syndrome. J Pharmacol Exp Ther 2013; 345: 215-224
  • 6 Yunger LM, Fowler PJ, Zarevics P. et al. Novel inhibitors of γ-aminobutyric acid (GABA) uptake: Anticonvulsant actions in rats and mice. J Pharmacol Exp Ther 1984; 228: 109-115
  • 7 Schousboe A, Madsen KK, Barker-Haliski ML. et al. The GABA Synapse as a Target for Antiepileptic Drugs: A Historical Overview Focused on GABA Transporters. Neurochem Res 2014; 39: 1980-1987
  • 8 Ali FE, Bondinell WE, Dandridge PA. et al. Orally Active and Potent Inhibitors of γ-Aminobutyric Acid Uptake. J Med Chem 1985; 28: 653-660
  • 9 Shimizu K, Ohtaki K, Matsubara K. et al. Carrier-mediated processes in blood-brain barrier penetration and neural uptake of paraquat. Brain Res 2001; 906: 135-142
  • 10 Nielsen EB, Suzdak PD, Andersen KE. et al. Characterization of tiagabine (NO-328), a new potent and selective GABA uptake inhibitor. Eur J Pharmacol 1991; 196: 257-266
  • 11 Bjorge S, Black A, Bockbrader H. et al. Synthesis and metabolic profile of Cl-966: A potent, orally-active inhibitor of GABA uptake. Drug Dev Re 1990; 21: 189-193
  • 12 Taylor CP, Vartanian MG, Schwarz RD. et al. Pharmacology of Cl-966: A potent GABA uptake inhibitor, in vitro and in experimental animals. Drug Dev Res 1990; 21: 195-215
  • 13 Falch E, Krogsgaard-Larsen P. Gaba uptake inhibitors containing mono- and diarylmethoxyalkyl N-substituents. Drug Des Deliv 1989; 4: 205-215
  • 14 Pardridge WM, Oldendorf WH. Kinetic analysis of blood-brain barrier transport of amino acids. BBA – Biomembr 1989; 4: 205-215
  • 15 Boado RJ, Li JY, Nagaya M. et al. Selective expression of the large neutral amino acid transporter at the blood-brain barrier. Proc Natl Acad Sci U S A 1999; 96: 12079-12084
  • 16 Löscher W. Anticonvulsant action in the epileptic gerbil of novel inhibitors of GABA uptake. Eur J Pharmacol 1985; 110: 103-108
  • 17 Killian DM, Hermeling S, Chikhale PJ. Targeting the cerebrovascular large neutral amino acid transporter (LAT1) isoform using a novel disulfide-based brain drug delivery system. Drug Deliv 2007; 14: 25-31
  • 18 Walker I, Nicholls D, Irwin WJ. et al. Drug delivery via active transport at the blood-brain barrier: affinity of a prodrug of phosphonoformate for the large amino acid transporter. Int J Pharm 1994; 104: 157-167
  • 19 Bonina FP, Arenare L, Palagiano F. et al. Synthesis, stability, and pharmacological evaluation of nipecotic acid prodrugs. J Pharm Sci 1999; 88: 561-567
  • 20 Gynther M, Laine K, Ropponen J. et al. Large neutral amino acid transporter enables brain drug delivery via prodrugs. J Med Chem 2008; 51: 932-936
  • 21 Puris E, Gynther M, Huttunen J. et al. L-type amino acid transporter 1 utilizing prodrugs: How to achieve effective brain delivery and low systemic exposure of drugs. J Control Release 2017; 261: 93-104
  • 22 Peura L, Malmioja K, Laine K. et al. Large amino acid transporter 1 (LAT1) prodrugs of valproic acid: New prodrug design ideas for central nervous system delivery. Mol Pharm 2011; 8: 1857-1866
  • 23 Peura L, Malmioja K, Huttunen K. et al. Design, synthesis and brain uptake of lat1-targeted amino acid prodrugs of dopamine. Pharm Res 2013; 2523-2537
  • 24 Ylikangas H, Malmioja K, Peura L. et al. Quantitative insight into the design of compounds recognized by the L-type amino acid transporter 1 (LAT1). Chem. Med Chem 2014; 9: 2699-2707
  • 25 Kim YC, Zhao LX, Kim TH. et al. Design and synthesis of anticonvulsive agents as γ-vinyl GABA-based potential dual acting prodrugs and their biological activities. Bioorganic Med Chem Lett 2000; 10: 609-613
  • 26 Napolitano C, Scaglianti M, Scalambra E. et al. Carnitine Conjugate of Nipecotic acid: A new example of dual prodrug. Molecules 2009; 14: 3268-3274
  • 27 Seth A, Sharma PA, Tripathi A. et al. Design, Synthesis, Evaluation and Computational Studies of Nipecotic Acid-Acetonaphthone Hybrids as Potential Antiepileptic Agents. Med Chem (Los Angeles) 2018; 14: 409-426
  • 28 Löscher W. Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. Seizure 2011; 20: 359-368
  • 29 Kowalczyk P, Sałat K, Höfner GC. et al. Synthesis, biological evaluation and structure-activity relationship of new GABA uptake inhibitors, derivatives of 4-aminobutanamides. Eur J Med Chem 2014; 83: 256-273
  • 30 Shiotsuki H, Yoshimi K, Shimo Y. et al. A rotarod test for evaluation of motor skill learning. J Neurosci Methods 2010; 189: 180-185
  • 31 Kulkarni SK, Joseph P. Psychopharmacological profile of siotone granules®, a herbal preparation. Indian Drugs 1998; 35: 536-554
  • 32 Aydin S, Demir T, Öztürk Y. et al. Analgesic activity of Nepeta italica L. Phyther Res 1999; 13: 20-23
  • 33 Steru L, Chermat R, Thierry B. et al. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl) 1985; 85: 367-370
  • 34 Singh D, Mishra A, Goel RK. Effect of saponin fraction from Ficus religiosa on memory deficit, and behavioral and biochemical impairments in pentylenetetrazol kindled mice. Epilepsy Behav 2013; 27: 206-211
  • 35 Nassereddine-Sebaei M, Crider AM, Carroll RT. et al. Determination of m-nitrophenol and nipecotic acid in mouse tissues by high-performance liquid chromatography after administration of the anticonvulsant m-nitrophenyl-3-piperidinecarboxylate hydrochloride. J Pharm Sci 1993; 82: 39-43
  • 36 Bauer J, Cooper-Mahkorn D. Tiagabine: Efficacy and safety in partial seizures - Current status. Neuropsychiatr Dis Treat 2008; 4: 731-736
  • 37 De Deyn PP, D’Hooge R, Marescau B. et al. Chemical models of epilepsy with some reference to their applicability in the development of anticonvulsants. Epilepsy Res 1992; 1992: 87-110